8-K: Exelixis Announces Preliminary Fiscal Year 2024 Results, Provides 2025 Guidance, and Updates Pipeline

Exelixis reports strong preliminary FY2024 financial results, offers FY2025 guidance, and highlights key milestones for its cabozantinib franchise and pipeline development.

Summary

• Exelixis announced preliminary unaudited financial results for fiscal year 2024 and provided financial guidance for fiscal year 2025.
• The company's cabozantinib franchise achieved approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024.
• Exelixis projects net product revenues of $1.95 billion to $2.05 billion for fiscal year 2025.
• Total revenues for 2024 are expected to be approximately $2.165 billion, with a guidance of $2.15 billion to $2.25 billion for 2025.
• Research and development expenses are estimated at $910 million for 2024 and are projected to be between $925 million and $975 million for 2025.
• Selling, general, and administrative expenses are expected to be around $495 million for 2024, with a guidance range of $475 million to $525 million for 2025.
• The company's cash and marketable securities are approximately $1.75 billion as of the end of fiscal year 2024.
• Exelixis anticipates a potential regulatory approval and commercial launch of CABOMETYX for previously treated advanced neuroendocrine tumors (NET), with a PDUFA target action date of April 3, 2025.
• The company is expanding and accelerating the zanzalintinib pivotal trial program, with multiple data readouts expected in 2025.
• Exelixis expects to initiate a phase 3 pivotal trial for zanzalintinib in patients with advanced NET in the first half of 2025.
• The company plans to advance three biotherapeutics programs into clinical development in 2025, including XB628, XB064, and XB371.
• Exelixis repurchased $205.6 million of its common stock under its stock repurchase program as of the end of fiscal year 2024, at an average price of $33.62 per share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, promising pipeline developments, and a clear strategy for future growth. The company's strong balance sheet and commitment to returning capital to shareholders further contribute to the positive sentiment.

Positives

• The cabozantinib franchise achieved approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024, demonstrating strong commercial performance.
• Exelixis projects net product revenues of $1.95 billion to $2.05 billion for fiscal year 2025, indicating continued growth.
• The company has a strong balance sheet with approximately $1.75 billion in cash and marketable securities.
• Exelixis is expanding its pipeline with multiple data readouts expected for zanzalintinib and other programs in 2025.
• The company is returning capital to shareholders through a stock repurchase program, having repurchased $205.6 million of its common stock as of the end of fiscal year 2024.

Negatives

• The preliminary financial results are unaudited and subject to change, which introduces some uncertainty.
• The 2025 net product revenues guidance does not include potential revenues from the U.S. regulatory approval and commercial launch of CABOMETYX for NET, indicating a reliance on this approval for achieving the higher end of the guidance.
• Research and development expenses are projected to increase in 2025, which could impact profitability.

Risks

• The regulatory review process for cabozantinib in NET is subject to the risk that the FDA may not approve it in a timely fashion, if at all.
• The success of zanzalintinib and other pipeline programs depends on demonstrating safety and efficacy in clinical testing.
• Exelixis depends on its relationships with collaboration partners, and their performance could impact the company's results.
• Market competition and the potential for generic versions of Exelixis' marketed products could impact future revenues.
• Unexpected adverse safety events or additional data analyses of clinical trials could negatively impact the company's prospects.

Future Outlook

Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as well as multiple data readouts for zanzalintinib and across its diversified pipeline. The company aims to grow cabozantinib franchise revenues, accelerate and expand its zanzalintinib pivotal development program, and advance its diversified therapeutic pipeline.

Management Comments

• Michael M. Morrissey, Ph.D., President & CEO, stated that Exelixis had a very successful 2024 and is carrying that momentum into the new year.
• Dr. Morrissey believes zanzalintinib has the potential to surpass cabozantinib's scope and scale in the coming years and become an important component of the company's midand long-term revenue growth.
• Dr. Morrissey mentioned that the company will maintain a balanced approach to capital allocation, leveraging its strong balance sheet to execute on business development opportunities and return capital to shareholders.

Industry Context

Exelixis is focused on oncology and is innovating next-generation medicines and regimens at the forefront of cancer care. The company is expanding its product portfolio to target an expanding range of tumor types and indications with its pipeline of small molecules, antibody-drug conjugates, and other biotherapeutics.

Comparison to Industry Standards

• Exelixis' cabozantinib franchise competes with other tyrosine kinase inhibitors (TKIs) in the oncology space, such as sunitinib and regorafenib.
• The company's zanzalintinib program aims to become the vascular endothelial growth factor receptor TKI of choice, suggesting a competitive landscape with other VEGF inhibitors.
• Exelixis' pipeline of antibody-drug conjugates (ADCs) puts it in competition with companies like Seagen and ImmunoGen, which are also developing ADCs for cancer treatment.
• The company's focus on GU and GI oncology aligns with the broader industry trend of developing targeted therapies for specific tumor types.

Stakeholder Impact

• Shareholders can expect continued growth and potential returns through the stock repurchase program.
• Patients may benefit from the potential approval and launch of new therapies, such as CABOMETYX for NET and zanzalintinib for various tumor types.
• Employees can expect continued investment in research and development and potential career opportunities as the company expands its pipeline.
• Collaboration partners can expect continued collaboration and potential for new partnerships as Exelixis executes on its business development strategy.

Next Steps

• Exelixis will report its audited financial results for the fiscal year ended January 3, 2025, on February 11, 2025.
• The company is preparing for the potential commercial launch of CABOMETYX for the treatment of patients with previously treated advanced NET following the FDA's decision on its sNDA, with a PDUFA target action date of April 3, 2025.
• Exelixis expects to initiate STELLAR-311, a phase 3 pivotal trial evaluating zanzalintinib compared with everolimus as a first oral therapy in patients with advanced NET, in the first half of 2025.
• The company plans to present data from the XL309 program at a scientific meeting in 2025.
• Exelixis anticipates advancing three biotherapeutics programs into clinical development in 2025 and expects to file IND applications for these compounds if preclinical data continue to be supportive.

Key Dates